Business Context and Reporting Period
Company: Kindly MD, Inc. (Note: Input metadata referenced "Nakamoto Inc.", but the filing text identifies the registrant as Kindly MD, Inc., trading as KDLY on Nasdaq).
Reporting Period: Quarterly Report (Form 10-Q) for the fiscal quarter ended September 30, 2024.
Business Overview: Kindly MD is a patient-first healthcare and data company focused on value-based care, reducing opioid use, and providing alternative medicine education. Revenue streams include patient care services, product retail sales, and service affiliate agreements.
Filer Status: Non-accelerated filer, Smaller reporting company, Emerging growth company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenues | $647,867 | $869,268 | $2,115,953 | $3,009,151 |
| Net Loss | $(1,014,147) | $(515,146) | $(2,616,126) | $(1,292,533) |
| Loss Per Share (Basic/Diluted) | $(0.17) | $(0.11) | $(0.50) | $(0.29) |
| Cash and Cash Equivalents (End of Period) | $3,642,944 (as of Sept 30, 2024) | |||
| Working Capital | $3,215,466 (as of Sept 30, 2024) | |||
| Net Cash Used in Operating Activities | N/A | N/A | $(2,172,361) | $(240,806) |
| Net Cash Provided by Financing Activities | N/A | N/A | $5,303,096 | $219,553 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 25.5% in Q3 2024 compared to Q3 2023, and 29.7% on a year-to-date basis. Management attributes this to a strategic shift from cash-pay patient services to insurance billing (Medicare, Medicaid, commercial payers), which has a longer reimbursement cycle.
- Expense Growth: Operating expenses increased 22.9% in Q3 2024. Salaries and wages rose 14.4% due to hiring for data management and compliance/billing infrastructure. General and administrative expenses surged 54.8% due to professional fees and insurance costs associated with becoming a public company.
- Liquidity Transformation: Cash and cash equivalents increased from $525,500 at year-end 2023 to $3,642,944 at September 30, 2024. This was driven primarily by the Initial Public Offering (IPO) completed on June 3, 2024, which generated net proceeds of approximately $5.86 million.
- Debt Settlement: The company repaid outstanding 10% OID promissory notes totaling $463,534 in connection with the IPO, issuing common stock to note holders and extinguishing a derivative liability.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes the IPO proceeds provide sufficient liquidity to meet obligations for at least the next 12 months. The company is transitioning from a cash-burn model to one aiming for sustained cash flow generation.
- Strategic Focus: The company is prioritizing the expansion of insurance billing capabilities and the integration of data analysis to improve patient outcomes and reduce opioid use.
- Stock Repurchase Program: On October 15, 2024 (subsequent event), the Board approved a program to repurchase up to $500,000 of common stock. No shares have been purchased yet.
- Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024. The company does not currently maintain sufficient controls to ensure timely reporting.
- Risks: Key risks include the need for additional capital if operations do not generate sufficient cash flow, reliance on third-party suppliers, and the inherent uncertainties of forward-looking statements regarding regulatory approvals and market conditions.
Investor Verification Checklist
- Revenue Recognition Timing: Verify the impact of the shift from cash-pay to insurance billing on future revenue recognition and cash flow cycles.
- Internal Controls: Review the specific deficiencies in disclosure controls and the remediation plan, given the "not effective" conclusion.
- Operating Burn Rate: Assess the sustainability of the current operating loss ($1.0M in Q3) against the $3.6M cash balance to determine the runway without further capital raises.
- Dilution: Monitor the impact of outstanding warrants (2.7M shares) and stock options (135K shares) on future earnings per share.
- Insurance Reimbursement: Confirm the growth trajectory of insurance reimbursements ($232k YTD 2024 vs $0 YTD 2023) to validate the strategic pivot.